CB8025-21845 entitled "A Phase 2, Randomized, Double Blind, Placebo Controlled, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of Seladelpar Administered for 24 Weeks in Adult Patients with Primary Sclerosing Cholangitis
Research Grant
Administered By
Radiology, Abdominal Imaging
Awarded By
CymaBay Therapeutics
Start Date
August 1, 2019
End Date
December 6, 2019
Administered By
Radiology, Abdominal Imaging
Awarded By
CymaBay Therapeutics
Start Date
August 1, 2019
End Date
December 6, 2019